Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers

Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · Aug 16, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on finding better ways to identify and understand early signs of Alzheimer's disease, especially in individuals who may be at risk of developing more serious cognitive issues. The researchers will gather various types of information, including brain scans (MRI), behavioral assessments, genetic data, and blood tests, to create models that can predict who might progress to more severe forms of memory problems or dementia.

To participate in this study, individuals should be between the ages of 50 and 79 and have completed at least eight years of education. Unfortunately, those with a history of certain neurological conditions, severe anxiety or depression, or those who cannot undergo MRI scans will not be eligible. If you choose to join, you can expect to undergo some tests and assessments that will help researchers learn more about the early signs of Alzheimer's, ultimately aiming to improve diagnosis and care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The inclusion criteria were 50-79 years old and having 8 or more years of education.
• Exclusion Criteria:
• • Participants with a history of stroke, other neurological disorders that could lead to cognitive impairment (Parkinson's disease, encephalitis, epilepsy, brain tumors, etc.), severe anxiety or depression, and contraindications for magnetic resonance imaging (MRI) were not enrolled.